[go: up one dir, main page]

GB202006974D0 - Chimaeric proteins and therapeutic agents - Google Patents

Chimaeric proteins and therapeutic agents

Info

Publication number
GB202006974D0
GB202006974D0 GBGB2006974.6A GB202006974A GB202006974D0 GB 202006974 D0 GB202006974 D0 GB 202006974D0 GB 202006974 A GB202006974 A GB 202006974A GB 202006974 D0 GB202006974 D0 GB 202006974D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic agents
chimaeric proteins
chimaeric
proteins
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2006974.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB2006974.6A priority Critical patent/GB202006974D0/en
Publication of GB202006974D0 publication Critical patent/GB202006974D0/en
Priority to US17/924,695 priority patent/US20250270519A1/en
Priority to CA3178612A priority patent/CA3178612A1/en
Priority to JP2022569162A priority patent/JP7779861B2/en
Priority to AU2021270376A priority patent/AU2021270376A1/en
Priority to EP21727522.1A priority patent/EP4149630A2/en
Priority to PCT/GB2021/051138 priority patent/WO2021229221A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Plant Substances (AREA)
GBGB2006974.6A 2020-05-12 2020-05-12 Chimaeric proteins and therapeutic agents Ceased GB202006974D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2006974.6A GB202006974D0 (en) 2020-05-12 2020-05-12 Chimaeric proteins and therapeutic agents
US17/924,695 US20250270519A1 (en) 2020-05-12 2021-05-12 Chimaeric proteins and therapeutic agents
CA3178612A CA3178612A1 (en) 2020-05-12 2021-05-12 Target specific degraders and their medical use
JP2022569162A JP7779861B2 (en) 2020-05-12 2021-05-12 Target-specific degrading agents and their medical uses
AU2021270376A AU2021270376A1 (en) 2020-05-12 2021-05-12 Target specifc degraders and their medical use
EP21727522.1A EP4149630A2 (en) 2020-05-12 2021-05-12 Target specifc degraders and their medical use
PCT/GB2021/051138 WO2021229221A2 (en) 2020-05-12 2021-05-12 Chimaeric proteins and therapeutic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2006974.6A GB202006974D0 (en) 2020-05-12 2020-05-12 Chimaeric proteins and therapeutic agents

Publications (1)

Publication Number Publication Date
GB202006974D0 true GB202006974D0 (en) 2020-06-24

Family

ID=71134979

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2006974.6A Ceased GB202006974D0 (en) 2020-05-12 2020-05-12 Chimaeric proteins and therapeutic agents

Country Status (7)

Country Link
US (1) US20250270519A1 (en)
EP (1) EP4149630A2 (en)
JP (1) JP7779861B2 (en)
AU (1) AU2021270376A1 (en)
CA (1) CA3178612A1 (en)
GB (1) GB202006974D0 (en)
WO (1) WO2021229221A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230257725A1 (en) * 2021-10-22 2023-08-17 Massachusetts Institute Of Technology Minimal Peptide Fusions for Targeted Intracellular Degradation of FOXP3
WO2023192915A1 (en) * 2022-03-29 2023-10-05 New York University Monobodies selective to nras
CN114796525B (en) * 2022-04-25 2024-04-02 南方科技大学 Application of cell cycle regulatory protein inhibitors in tumor treatment
WO2024064200A2 (en) * 2022-09-20 2024-03-28 The Texas A&M University System Darpin-containing compositions and methods thereof
CN116731206A (en) * 2023-05-24 2023-09-12 南方科技大学 Chimeric ubiquitin ligase for targeted degradation of KRAS as well as preparation method and application thereof
CN117924517A (en) * 2024-01-02 2024-04-26 河北神宇生物技术有限公司 Targeted membrane-penetrating recombinant protein and application thereof
WO2025184400A1 (en) * 2024-02-28 2025-09-04 The Trustees Of The University Of Pennsylvania Lipid-mediated intracellular delivery of recombinant bioprotacs for rapid degradation of undruggable proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003282247A1 (en) * 2002-11-15 2004-06-15 Medical Research Council Anti-activated ras antibodies
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
US7867724B2 (en) * 2007-11-05 2011-01-11 California Institute Of Technology Compositions and method of treating hypoxia-associated diseases
CN112135637A (en) * 2018-01-10 2020-12-25 财团法人生物技术开发中心 Antibody PROTAC conjugates
US20210017503A1 (en) * 2018-03-16 2021-01-21 Cornell University Broad-spectrum proteome editing with an engineered bacterial ubiquitin ligase mimic

Also Published As

Publication number Publication date
JP2023525164A (en) 2023-06-14
CA3178612A1 (en) 2021-11-18
US20250270519A1 (en) 2025-08-28
EP4149630A2 (en) 2023-03-22
JP7779861B2 (en) 2025-12-03
WO2021229221A3 (en) 2021-12-16
WO2021229221A2 (en) 2021-11-18
AU2021270376A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
GB202006974D0 (en) Chimaeric proteins and therapeutic agents
IL285269A (en) Preparations and methods for the treatment of neurocognitive diseases
IL285270A (en) Preparations and methods for the treatment of neurocognitive diseases
MX2021008207A (en) Multi-functional fusion proteins and uses thereof.
IL275248A (en) Therapeutic enzyme fusion protein having a novel structure and use thereof
EP4034132A4 (en) ERK5 DEGRADING AGENTS USED AS THERAPEUTIC AGENTS IN CANCER AND INFLAMMATORY DISEASES
IL278394A (en) Agents binding modified antigen presented peptides and use of same
IL271837A (en) Novel therapeutic enzyme fusion protein and use thereof
IL310306A (en) Fibroblast activation protein inhibitors and use thereof
IL304734A (en) Therapeutic and diagnostic agents and uses thereof
GB202019475D0 (en) Therapeutic compounds and their use
GB202108572D0 (en) Therapeutic compounds and their use
IL292599A (en) Tmem219 antibodies and therapeutic uses thereof
IL302507A (en) Use of human serum albumin in treatment of diseases
GB202210731D0 (en) Therapeutic agents
IL308014A (en) Anti-galectin-9 antibodies and therapeutic uses thereof
GB202201137D0 (en) Therapeutic and diagnostic agents and uses thereof
IL275186A (en) Human anti-grp94 antibodies and uses
EP4509136A4 (en) Fusion protein and use thereof
IL324416A (en) Iinsecticidal protein and use thereof
AU2021901067A0 (en) Therapeutic agents and uses therefor
IL315387A (en) Human antibodies against activated protein c and uses thereof
AU2020901994A0 (en) Therapeutic agents and uses therefor
GB202303292D0 (en) Therapeutic epitopes and uses thereof
ZA202406022B (en) Insecticidal protein and uses thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)